- Home
- NEN vs SLS Comparison
NEN vs SLS Comparison
Compare NEN & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
NEN
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
Company Overview
Basic Information| Metric | NEN | SLS |
|---|---|---|
| Founded | 1977 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.7M | 208.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NEN | SLS |
|---|---|---|
| Price | $64.50 | $4.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 2.1K | ★ 10.4M |
| Earning Date | 03-12-2026 | 11-12-2025 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | ★ $87,362,592.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.39 | ★ N/A |
| Revenue Growth | ★ 7.63 | N/A |
| 52 Week Low | $63.00 | $0.85 |
| 52 Week High | $84.00 | $4.66 |
Technical Indicators
Market Signals| Indicator | NEN | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 92.90 |
| Support Level | $63.00 | $2.60 |
| Resistance Level | $64.50 | $3.99 |
| Average True Range (ATR) | 0.87 | 0.40 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 29.35 | 94.44 |
Price Performance
Historical ComparisonAbout NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.